- ProQR Therapeutics NV R&D Day TranscriptMar 29, 2023
- ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview TranscriptDec 22, 2022
- ProQR Therapeutics NV Management Call TranscriptAug 11, 2022
- ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call TranscriptApr 13, 2022
- ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call TranscriptFeb 11, 2022
- ProQR Therapeutics NV Analyst Event TranscriptNov 18, 2021
- ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- ProQR Therapeutics NV Axiomer RNA Call TranscriptSep 09, 2021
- ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald TranscriptMar 25, 2021
- ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP TranscriptMar 24, 2021
- ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- ProQR Therapeutics NV Expert Perspectives Call TranscriptFeb 22, 2021
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call TranscriptJul 20, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call TranscriptJun 22, 2020
ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) Transcript
Hi. Welcome, everyone, to the session, Finding a Needle in a Haystack, Drug Development Strategies for Rare Disease. I'm Yigal Nochomovitz one of the biotech analysts here at Citi. And it's my pleasure to have with me this afternoon 4 distinguished panelists from Dicerna Pharmaceuticals, Douglas Fambrough, the CEO; from Eiger BioPharmaceuticals, David Cory, President and CEO; from ProQR Therapeutics, Smital Shah, who is the CFO and CBO; and from Ultragenyx Pharmaceutical, Emil Kakkis, President and CEO. So welcome all of you. Thank you very, very much for participating in the panel.
And maybe just to start things off, if each of you could provide a very brief 2 to 3-minute introduction to the company, what does your pipeline look like, what are the key clinical and commercial catalysts that are coming up for each of you. Maybe we could start with Emil.
Sure. Thanks for having us, Yigal.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)